PRL3-specific inhibitor

A PRL3-specific inhibitor is a pharmacological agent designed to selectively target and inhibit the activity of Protein Tyrosine Phosphatase 4A3 (PRL3), also known as PTP4A3. PRL3 is a member of the phosphatase of regenerating liver (PRL) family and is recognized as an oncogenic phosphatase frequently overexpressed in various cancers, including colorectal, breast, and T-cell acute lymphoblastic leukemia (T-ALL). It plays a critical role in promoting tumor cell proliferation, migration, invasion, and survival. While pan-PRL inhibitors target multiple members of the family (PRL1, PRL2, and PRL3), specific inhibitors are developed to isolate the therapeutic impact of targeting PRL3 alone, potentially reducing off-target effects. Research in zebrafish models has explored these inhibitors for their potential to delay leukemia onset and progression, although their efficacy can vary compared to broader pan-PRL inhibition strategies.

Other names

PRL3 inhibitorPRL-3 inhibitorPRL 3 inhibitorPTP4A3 inhibitorPTP-4A3 inhibitorPTP 4A3 inhibitorPRL3-specific inhibitorPRL-3-specific inhibitorPRL 3-specific inhibitor